Matches in SemOpenAlex for { <https://semopenalex.org/work/W2187580324> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2187580324 abstract "Objective: To evaluate the comparative efficacy and safety of tamsulosin 0.4mg once daily verses finasteride in men with symptomatic benign prostatic hyperplasia. Patients and method: In this randomised study, 69 patients were enrolled. Of these 51 were receive tamsulosin 0.4 mg and 18 patients were receive finasteride 5 mg once daily for 12 weeks. The primary outcome measures (mean changes in total and /or individual I-PSS score, prostate volume and life style questionnaire) were compared from baseline to 12 weeks of study. Result: During study both drugs reduced the total and individual I-PSS scores, while tamsulosin significantly improved lower urinary tract symptoms compared to finasteride (p ≤0.0002) within 3-monts of therapy, (mean change in I-PSS scores from baseline to end of the study was 16.7 VS 9.0 in tamsulosin VS finasteride respectively). Improvement in symptoms score was 82.67% in tamsulosin compare to 45.50% in finasteride. The life style questionnaire was significantly improved in tamsulosin group. The prostate volume is slightly increased (0.75ml) in tamsulosin and 1.44 ml decreases in finasteride group during study. Adverse events were similar in both groups; most common observed adverse event was dizziness (4.34%) in tamsulosin similar to finasteride ((7.14 %). While sexual disorder (2.1%) delayed ejaculation was prominent in tamsulosin group. Conclusion: Once daily dosing of tamsulosin at bed time at a fix dose level (0.4mg) offers an efficient improvement in total and individual I-PSS score compare to finasteride. The prostate volume was increase in tamsulosin while it was decreased in finasteride group; adverse events other than ejaculatory disorder were similar similar in both groups. Tamsulosin is safe, well tolerated and significantly more effective than finasteride for short term treatment of symptomatic BPH." @default.
- W2187580324 created "2016-06-24" @default.
- W2187580324 creator A5016105867 @default.
- W2187580324 creator A5048182271 @default.
- W2187580324 creator A5048916858 @default.
- W2187580324 creator A5069910766 @default.
- W2187580324 date "2013-01-01" @default.
- W2187580324 modified "2023-09-23" @default.
- W2187580324 title "COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 mg) V/S (and) FINASTERIDE FOR SHORT-TERM TREATMENT OF PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA" @default.
- W2187580324 cites W107210901 @default.
- W2187580324 cites W1961722751 @default.
- W2187580324 cites W198934061 @default.
- W2187580324 cites W1993919317 @default.
- W2187580324 cites W2058172697 @default.
- W2187580324 cites W2064844805 @default.
- W2187580324 cites W2078327625 @default.
- W2187580324 cites W225105017 @default.
- W2187580324 cites W2293341447 @default.
- W2187580324 cites W2400376596 @default.
- W2187580324 cites W2804551733 @default.
- W2187580324 hasPublicationYear "2013" @default.
- W2187580324 type Work @default.
- W2187580324 sameAs 2187580324 @default.
- W2187580324 citedByCount "1" @default.
- W2187580324 countsByYear W21875803242017 @default.
- W2187580324 crossrefType "journal-article" @default.
- W2187580324 hasAuthorship W2187580324A5016105867 @default.
- W2187580324 hasAuthorship W2187580324A5048182271 @default.
- W2187580324 hasAuthorship W2187580324A5048916858 @default.
- W2187580324 hasAuthorship W2187580324A5069910766 @default.
- W2187580324 hasConcept C121608353 @default.
- W2187580324 hasConcept C126322002 @default.
- W2187580324 hasConcept C126894567 @default.
- W2187580324 hasConcept C197934379 @default.
- W2187580324 hasConcept C2775874879 @default.
- W2187580324 hasConcept C2776235491 @default.
- W2187580324 hasConcept C2777562237 @default.
- W2187580324 hasConcept C2777812360 @default.
- W2187580324 hasConcept C2779478474 @default.
- W2187580324 hasConcept C2780542891 @default.
- W2187580324 hasConcept C71924100 @default.
- W2187580324 hasConceptScore W2187580324C121608353 @default.
- W2187580324 hasConceptScore W2187580324C126322002 @default.
- W2187580324 hasConceptScore W2187580324C126894567 @default.
- W2187580324 hasConceptScore W2187580324C197934379 @default.
- W2187580324 hasConceptScore W2187580324C2775874879 @default.
- W2187580324 hasConceptScore W2187580324C2776235491 @default.
- W2187580324 hasConceptScore W2187580324C2777562237 @default.
- W2187580324 hasConceptScore W2187580324C2777812360 @default.
- W2187580324 hasConceptScore W2187580324C2779478474 @default.
- W2187580324 hasConceptScore W2187580324C2780542891 @default.
- W2187580324 hasConceptScore W2187580324C71924100 @default.
- W2187580324 hasLocation W21875803241 @default.
- W2187580324 hasOpenAccess W2187580324 @default.
- W2187580324 hasPrimaryLocation W21875803241 @default.
- W2187580324 hasRelatedWork W1567665160 @default.
- W2187580324 hasRelatedWork W1880992000 @default.
- W2187580324 hasRelatedWork W1912400660 @default.
- W2187580324 hasRelatedWork W2013892513 @default.
- W2187580324 hasRelatedWork W2020728098 @default.
- W2187580324 hasRelatedWork W2045661813 @default.
- W2187580324 hasRelatedWork W2049095189 @default.
- W2187580324 hasRelatedWork W2110308314 @default.
- W2187580324 hasRelatedWork W2111264969 @default.
- W2187580324 hasRelatedWork W2182092991 @default.
- W2187580324 hasRelatedWork W2402681117 @default.
- W2187580324 hasRelatedWork W2589035890 @default.
- W2187580324 hasRelatedWork W2786468047 @default.
- W2187580324 hasRelatedWork W2922501701 @default.
- W2187580324 hasRelatedWork W2997830417 @default.
- W2187580324 hasRelatedWork W3112191666 @default.
- W2187580324 hasRelatedWork W3192536826 @default.
- W2187580324 hasRelatedWork W3202390542 @default.
- W2187580324 hasRelatedWork W2183049967 @default.
- W2187580324 hasRelatedWork W2187208228 @default.
- W2187580324 isParatext "false" @default.
- W2187580324 isRetracted "false" @default.
- W2187580324 magId "2187580324" @default.
- W2187580324 workType "article" @default.